Alliance for mRNA Medicines, Inc.
Acronym: AMM
General Information
Identification Code: 526710351707-63
Website: [object Object]
Entity Form: A not-for-profit organization, incorporated under Delaware (United States) law.
Registration Category: Trade and business associations
Registration Date: 10/25/2023
EP Accredited Number: 0
Mission & Interests
Goals: The Alliance for mRNA Medicines (AMM) is an organization dedicated to advancing and advocating for mRNA and next-generation encoding RNA therapeutics and vaccines for the benefit of patients, public health, and society. Our mission is to propel the future of mRNA medicine, improve patients’ lives, and advance scientific knowledge by convening and empowering mRNA industry leaders, innovators, scientists, and other key stakeholders.
Interests Represented: Promotes their own interests or the collective interests of their members
Interests:
- Competition
- Consumers
- Digital economy and society
- Public health
- Regional policy
- Single market
- Trans-European Networks
Levels of Interest:
- global
Activities
Main EU Legislative Proposals: AMM focuses on mRNA supply, production, manufacturing, discovery, and workforce organizations. AMM also monitors and analyzes initiatives, policies, legislation, and regulations impacting the mRNA industry. In addition to participating in numerous public consultations and industry stakeholder workshops on multiple topics within the mRNA sphere, AMM and its members are engaged in bringing about regulatory harmonization between the European Medicines Agency and other global counterparts. AMM also follows initiatives and policies on innovation in bioscience, biomanufacturing, pharmaceutical distribution, and other pressing issues of interest to the pharmaceutical industry. This includes the EU General Pharmaceuticals Legislation.
Communication Activities: AMM maintains a communications/public relations program with an emphasis on European Union and United States legislative, regulatory, and business issues affecting mRNA-related organizations. In addition to traditional media, AMM is active on social media through LinkedIn.
Inter-institutional or Unofficial Groupings: N/A
Head Office
Address: 601 New Jersey Ave NWSuite 350
Post Code: 20001
City: Washington D.C.
Country: UNITED STATES
Phone: [object Object]
EU Office
Address: 601 New Jersey Ave NWSuite 350
Post Code: 20001
City: Washington D.C.
Country: UNITED STATES
Phone: [object Object]
Financial Data
New Organisation: true
Current Year: [object Object]
Complementary Information: The organization has just formed. The estimated annual costs as AMM begins is roughly 50,000 to 100,000 Euros.
Membership Information
Members10 Percent: 0
Members25 Percent: 4
Members50 Percent: 0
Members75 Percent: 0
Members: 4
Members F T E: 1
Structure
Structure Type: Structure
Is Member Of: (Subject to change)
o Acuitas
o Precision Medicines Group
o Replicate
o Laronde
o Arcturus
o TX A&M EES
o CSL
o Cytonus
o JHU mRNA Innovation Center
o Danaher
o Akron
o Ginkgo Bioworks
o Exothera
o Quantoom Biosciences
o Curapath
o CureVac
o MJH Life Sciences
o MaxCyte
o BioNTech
o Maravai
o Whywevax
Organisation Members: None yet, the organization has just formed.